RSPI (RespireRx Pharmaceuticals) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2023)


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals LT-Debt-to-Total-Asset?

RespireRx Pharmaceuticals RSPI 12 LT-Debt-to-Total-Asset is 0.00 as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. RespireRx Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.00.

RespireRx Pharmaceuticals's long-term debt to total assets ratio stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00).

RespireRx Pharmaceuticals  (OTCPK:RSPI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

RespireRx Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

RespireRx Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals LT-Debt-to-Total-Asset Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals LT-Debt-to-Total-Asset Calculation

RespireRx Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=0/0.023
=

RespireRx Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )/Total Assets (Q: Sep. 2023 )
=0/0.109
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
RespireRx Pharmaceuticals (RSPI) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' LT-Debt-to-Total-Asset too high?
RespireRx Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.00. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' LT-Debt-to-Total-Asset compare to CNBX and NAVB?
RespireRx Pharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price